New combo therapy shows promise for rare cancers
NCT ID NCT03290079
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 33 times
Summary
This study tested a combination of two drugs, pembrolizumab and lenvatinib, in 20 people with advanced neuroendocrine tumors that had worsened despite prior treatments. The goal was to see if the combination could shrink tumors or slow cancer growth. The study measured how many patients responded, how long the response lasted, and how safe the treatment was.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.